<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276207</url>
  </required_header>
  <id_info>
    <org_study_id>17277</org_study_id>
    <secondary_id>I8B-MC-ITST</secondary_id>
    <secondary_id>2019-003493-13</secondary_id>
    <nct_id>NCT04276207</nct_id>
  </id_info>
  <brief_title>A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps</brief_title>
  <official_title>Effects of LY900014 on Recovery From Hyperglycemia Compared to Humalog in Subjects With Type 1 Diabetes Mellitus (T1DM) on Continuous Subcutaneous Insulin Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare LY900014 to insulin lispro (Humalog) in
      participants with type 1 diabetes who are using an insulin pump and have high blood sugar
      after eating. For each participant, the study will last about two to nine weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">August 13, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 13, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Recovery from Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog)</measure>
    <time_frame>Day 1: Baseline up to 5 hours after missed meal bolus</time_frame>
    <description>Time to recovery from hyperglycemia following administration of LY900014 and insulin lispro (Humalog)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Recovery from Hyperglycemia Following Administration of LY900014 and Insulin Lispro (Humalog)</measure>
    <time_frame>Day 2: Baseline up to 5 hours after pump suspension</time_frame>
    <description>Time to recovery from hyperglycemia following administration of LY900014 and insulin lispro (Humalog)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Maximum Observed Plasma Glucose (PGmax) Following Administration of LY900014 and Insulin Lispro (Humalog) by Day</measure>
    <time_frame>Day 1: Baseline up to 5 hours after missed meal bolus and Day 2: Baseline up to 5 hours after pump suspension</time_frame>
    <description>PD: PGmax following administration of LY900014 and insulin lispro (Humalog) by day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Time to Maximum Observed Insulin Lispro Concentration (Tmax) Following Administration of LY900014 and Insulin Lispro (Humalog) by Day</measure>
    <time_frame>Day 1: Baseline up to 5 hours after missed meal bolus and Day 2: Baseline up to 5 hours after pump suspension</time_frame>
    <description>PK: Tmax following administration of LY900014 and insulin lispro (Humalog) by day</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>LY900014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro (Humalog)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin lispro (Humalog) administered by CSII in one of two study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY900014</intervention_name>
    <description>Administered by CSII</description>
    <arm_group_label>LY900014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered by CSII</description>
    <arm_group_label>Insulin Lispro (Humalog)</arm_group_label>
    <other_name>Humalog</other_name>
    <other_name>LY275585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female participants with type 1 diabetes

          -  Body mass index (BMI) between 18.5 and 30.0 kilograms per square meter, inclusive

          -  Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%)

          -  Using CSII and stable insulin regimen for at least 3 months prior to inclusion into
             the trial

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to investigational medical product(s) or related
             products

          -  Receipt of any medicinal product in clinical development within 30 days or at least 5
             half-lives of the related substances and their metabolites (whichever is longer)
             before randomization in this trial

          -  Known slowing of gastric emptying and or gastrointestinal surgery that, in the opinion
             of the investigator, might change gastrointestinal motility and food absorption

          -  Proliferative retinopathy or maculopathy as judged by the Investigator based on a
             recent (less than 1.5 years) ophthalmologic examination

          -  Widespread subcutaneous lipodystrophy in the abdomen

          -  Current use of any glucose-lowering agents other than insulin within 3 months prior to
             screening

          -  Chronic or recent use of corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Mainz GmbH &amp; Co. KG</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4961312162600</phone>
    </contact>
    <investigator>
      <last_name>Leona Plum-MÃ¶rschel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

